Viridian Therapeutics, Inc. $VRDN Stock Holdings Reduced by Rosalind Advisors Inc.

Key Points

• Rosalind Advisors trimmed its position in Viridian Therapeutics by 14.3%, selling 100,000 shares to hold 600,000 shares worth about $12.95M, which is 4.6% of its portfolio and left it as the fund's ninth-largest holding; Rosalind owned 0.63% of VRDN at quarter-end.
• Other institutions were net buyers: Fisher Asset Management boosted its stake by 135.6% to 1,201,226 shares (~$25.9M) and Rice Hall James increased to 851,663 shares, while new positions were opened by Simplify Asset Management and Propel Bio Management.
• Fundamentals and coverage diverge—analysts show a consensus Moderate Buy with a $42.21 average target, but Viridian missed the quarter (EPS $(1.08) vs. $(0.90) est., revenue $0.13M vs. $15.75M est.), and insiders own 1.58% with a recent small insider sale.

Rosalind Advisors Inc. lowered its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 14.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 600,000 shares of the company's stock after selling 100,000 shares during the period. Viridian Therapeutics accounts for 4.6% of Rosalind Advisors Inc.'s portfolio, making the stock its 9th largest holding. Rosalind Advisors Inc. owned 0.63% of Viridian Therapeutics worth $12,948,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Simplify Asset Management Inc. bought a new position in shares of Viridian Therapeutics during the 3rd quarter valued at $1,079,000. Fisher Asset Management LLC lifted its stake in shares of Viridian Therapeutics by 135.6% in the 3rd quarter. Fisher Asset Management LLC now owns 1,201,226 shares of the company's stock valued at $25,922,000 after purchasing an additional 691,267 shares during the last quarter. Propel Bio Management LLC bought a new stake in Viridian Therapeutics in the third quarter worth $1,942,000. Y Intercept Hong Kong Ltd boosted its holdings in Viridian Therapeutics by 430.3% in the third quarter. Y Intercept Hong Kong Ltd now owns 64,594 shares of the company's stock worth $1,394,000 after purchasing an additional 52,414 shares in the last quarter. Finally, Rice Hall James & Associates LLC increased its position in Viridian Therapeutics by 65.2% during the third quarter. Rice Hall James & Associates LLC now owns 851,663 shares of the company's stock worth $18,379,000 after buying an additional 336,040 shares during the last quarter.

Insider Transactions at Viridian Therapeutics

In other Viridian Therapeutics news, insider Jennifer Tousignant sold 2,272 shares of Viridian Therapeutics stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $31.16, for a total value of $70,795.52. The sale was disclosed in a filing with the SEC, which is available through this link. 1.58% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on VRDN. Wedbush restated an "outperform" rating and set a $44.00 target price on shares of Viridian Therapeutics in a report on Wednesday. Needham & Company LLC reissued a "buy" rating and set a $42.00 price objective on shares of Viridian Therapeutics in a report on Wednesday, February 4th. Evercore reissued an "outperform" rating and issued a $44.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, January 20th. William Blair began coverage on Viridian Therapeutics in a report on Wednesday, December 3rd. They issued an "outperform" rating for the company. Finally, Wall Street Zen cut Viridian Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 7th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $42.21.

Viridian Therapeutics Stock Down 0.7%

VRDN stock opened at $28.41 on Friday. The stock has a market capitalization of $2.90 billion, a price-to-earnings ratio of -8.64 and a beta of 1.00. The company has a 50-day moving average of $30.55 and a two-hundred day moving average of $27.08. Viridian Therapeutics, Inc. has a 52-week low of $9.90 and a 52-week high of $34.29. The company has a debt-to-equity ratio of 0.08, a current ratio of 12.65 and a quick ratio of 12.65.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.18). Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%.The business had revenue of $0.13 million during the quarter, compared to the consensus estimate of $15.75 million. As a group, equities research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc NASDAQ: VRDN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company's lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.